Peptic Ulcer Disease (PUD) is a common gastrointestinal disorder characterized by mucosal breaks in the lining of the stomach (gastric ulcers) or the first part of the small intestine (duodenal ulcers) that extend through the muscularis mucosae. PUD results from an imbalance between aggressive factors, such as gastric acid and pepsin, and protective mucosal defense mechanisms, including mucus production, bicarbonate secretion, and mucosal blood flow. Despite advancements in acid-suppression therapy, PUD remains a significant cause of morbidity, particularly due to serious complications like hemorrhage and perforation.
Primary Etiologies: H. pylori and NSAIDs
The vast majority of peptic ulcers are caused by either chronic infection with the bacterium Helicobacter pylori or the use of Non-Steroidal Anti-inflammatory Drugs (NSAIDs).
Helicobacter pylori: This spiral-shaped, Gram-negative bacterium colonizes the gastric antrum, where it produces urease, an enzyme that converts urea into carbon dioxide and ammonia. The resulting alkaline microenvironment protects the bacterium from gastric acid. H. pylori causes mucosal damage through the release of bacterial toxins (such as CagA and VacA) and by inducing a chronic inflammatory host response. This localized inflammation leads to hypergastrinemia, increased acid secretion, and progressive damage to the duodenal and gastric mucosa, culminating in ulcer formation.
Non-Steroidal Anti-inflammatory Drugs (NSAIDs): Chronic NSAID use is the second leading cause of PUD. NSAIDs inhibit cyclooxygenase (COX) enzymes, particularly COX-1, which is responsible for the synthesis of cytoprotective prostaglandins in the gastrointestinal tract. Prostaglandins play a critical role in maintaining mucosal integrity by stimulating mucus and bicarbonate secretion, maintaining mucosal blood flow, and promoting epithelial cell renewal. By depleting mucosal prostaglandins, NSAIDs render the gastroduodenal lining highly vulnerable to acid-induced injury.
Clinical Presentation and Diagnosis
The classic symptom of PUD is dyspepsia, described as burning or gnawing epigastric pain. The timing of the pain relative to food intake can help differentiate the ulcer location. Gastric ulcer pain is often exacerbated by meals, leading to weight loss and avoidance of food. Conversely, duodenal ulcer pain typically occurs 2 to 3 hours after a meal or during the night when the stomach is empty, and is characteristically relieved by food or antacids.
Diagnosis is established via upper endoscopy (Esophagogastroduodenoscopy or EGD), which allows for direct visualization of the ulcer, assessment of size and location, and biopsy of gastric ulcers to rule out malignancy. Testing for H. pylori is mandatory in all patients with PUD. Non-invasive testing methods include the urea breath test, stool antigen test, and serology. Invasive testing is performed on biopsy specimens obtained during endoscopy and includes the rapid urease test (CLOtest), histology, and bacterial culture.
💡 💡 Clinical Pearl: Eradication Confirmation
Always confirm Helicobacter pylori eradication at least 4 weeks after completing therapy and after withholding PPIs for at least 2 weeks, using a urea breath test or stool antigen test to avoid false-negative results.
Treatment Strategies and Management
The management of PUD is determined by the underlying etiology. For H. pylori-positive ulcers, eradication therapy is primary. Current guidelines recommend first-line bismuth quadruple therapy (consisting of a PPI, bismuth subsalicylate, metronidazole, and tetracycline) for 14 days, particularly in areas with high clarithromycin resistance. Alternatively, clarithromycin triple therapy (PPI, clarithromycin, and amoxicillin or metronidazole) is used only in patients with no prior macrolide exposure and in regions with low resistance rates.
For NSAID-induced ulcers, the offending drug should be discontinued immediately. If NSAID therapy is clinically mandatory, patients should switch to a selective COX-2 inhibitor (such as celecoxib) and be co-prescribed a PPI or misoprostol (a synthetic prostaglandin E1 analog) for mucosal protection. PPIs are the standard pharmacotherapy for promoting ulcer healing, typically administered for 4 to 8 weeks depending on ulcer size and location.
Understanding PUD and distinguishing it from other causes of epigastric pain, such as GERD Reflux, is important. Additionally, acute gastric presentations must be differentiated from infectious etiologies like Acute Gastroenteritis.
💡 Frequently Asked Questions (FAQ)
Q1: How do NSAIDs cause stomach ulcers?
A1: NSAIDs block cyclooxygenase (COX) enzymes, which are needed to produce prostaglandins. Prostaglandins maintain the stomach’s protective mucus layer and regulate gastric blood flow; without them, the stomach acid damages the mucosal lining.
Q2: Does eating spicy food cause peptic ulcers?
A2: No, spicy foods and stress do not cause peptic ulcers, though they can aggravate symptoms of an existing ulcer. The primary causes remain H. pylori infection and chronic NSAID use.
Q3: What are the warning signs of a bleeding peptic ulcer?
A3: Warning signs include vomiting blood (red or “coffee-ground” appearance), passing black, tarry stools (melena), sudden severe abdominal pain, and feeling faint or dizzy. These require immediate emergency medical care.
📚 References & Sources
- Chey, W. D., Leontiadis, G. I., Howden, C. W., & Moss, S. F. (2017). ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. American Journal of Gastroenterology, 112(2), 212-239.
- Lanza, F. L., Chan, F. K., & Quigley, E. M. (2009). Guidelines for prevention of NSAID-related ulcer complications. American Journal of Gastroenterology, 104(3), 728-738.